Based on the aggregated intelligence of 150,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, Chinese pharmaceuticals maker China Sky One Medical (Nasdaq: CSKI) has earned a respected four-star ranking.

With that in mind, let's take a closer look at China Sky's business and see what CAPS investors are saying about the stock right now.

China Sky facts

Headquarters (Founded)

Harbin, China (1994)

Market Cap

$267.1 million


Personal products

Trailing-12-Month Revenue

$126.2 million


Chairman/CEO Yan-Qing Liu

CFO Yu-bo Hao

Return on Equity (Average, Past 3 Years)



$56.3 million / $0

Other Highly Rated Drug Stocks

Pfizer (NYSE: PFE)
Merck (NYSE: MRK)
GlaxoSmithKline (NYSE: GSK)

Other Highly Rated Chinese Stocks

American Oriental Bioengineering (NYSE: AOB)
GigaMedia (Nasdaq: GIGM)
Melco Crown Entertainment (Nasdaq: MPEL)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 95% of the 433 members who have rated China Sky believe the stock will outperform the S&P 500 going forward. These bulls include All-Star danielthebear, who is ranked in the top 6% of our community, and Boatyzaffa.

Late last month, danielthebear listed several reasons why China Sky looked bright:

-excellent margins
-a great P/E
-sustainable earnings that everyone and their grandmother expect to grow
-exposure to China (this is not worth as much as it once was but they are in much better shape than the US)…
-no debt
-34% ROE

In a pitch from late last year, Boatzyaffa expands on the healthy opportunity:

[China Sky] is a great value and growth stock! ... Fundamentally, the company looks very strong with zero debt, a 34.33% return on Equity, and an EPS of 2.19. ... Also worth mentioning is the fact that 36.81% of the outstanding shares are held by insiders. In all I believe [China Sky] looks to be a great stock to add to a diversified portfolio.

What do you think about China Sky, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!  

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Pfizer is a Motley Fool Inside Value pick, and Melco is a choice of Global Gains. The Fool owns shares of GlaxoSmithKline. The Fool's disclosure policy always gets a perfect score.